Eupraxia Pharmaceuticals (TSE:EPRX)
TSX:EPRX
Want to see TSE:EPRX full AI Analyst Report?
Top Page
Eupraxia Pharmaceuticals
(TSX:EPRX)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$9.50
▼(-2.46% Downside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by pre-revenue operations, widening losses, and ongoing/accelerating cash burn that can necessitate future financing. A strengthened, low-leverage balance sheet provides some resilience, while technical indicators are neutral-to-mixed and valuation is constrained by negative earnings and no dividend data.
Positive Factors
Proprietary DiffuSphere platform
The DiffuSphere platform is a durable competitive asset: controlled, local delivery can reduce systemic exposure and enable differentiated dosing schedules. Platform scalability across GI, urology and OA increases optionality and the potential to extend lifetime value beyond a single asset.
Negative Factors
Pre-revenue operations
Being pre-revenue keeps commercial and execution risk front and center: with no product sales, the business depends entirely on successful clinical development and future commercialization, delaying positive cash generation and making long-term returns contingent on trial outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary DiffuSphere platform
The DiffuSphere platform is a durable competitive asset: controlled, local delivery can reduce systemic exposure and enable differentiated dosing schedules. Platform scalability across GI, urology and OA increases optionality and the potential to extend lifetime value beyond a single asset.
Read all positive factors
Eupraxia Pharmaceuticals (EPRX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$616.31M
Dividend YieldN/A
Average Volume (3M)53.43K
Price to Earnings (P/E)―
Beta (1Y)0.96
Revenue GrowthN/A
EPS Growth-34.19%
CountryCA
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.24
Shares Outstanding61,503,180
10 Day Avg. Volume45,847
30 Day Avg. Volume53,430
Financial Highlights & Ratios
PEG Ratio-5.41
Price to Book (P/B)5.04
Price to Sales (P/S)0.00
P/FCF Ratio-13.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$22.86Price Target Upside134.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.17
Revenue Forecast (FY)N/A
Eupraxia Pharmaceuticals Business Overview & Revenue Model
Company Description
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clin...
How the Company Makes Money
null...
Eupraxia Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -326.06K | -241.88K | -235.25K | -209.91K | -193.27K | -111.53K |
| EBITDA | -49.36M | -38.86M | -33.72M | -37.40M | -22.14M | -21.96M |
| Net Income | -46.92M | -39.25M | -34.94M | -37.39M | -23.26M | -22.99M |
Balance Sheet | ||||||
| Total Assets | 145.46M | 85.99M | 50.24M | 26.72M | 25.88M | 31.22M |
| Cash, Cash Equivalents and Short-Term Investments | 138.98M | 80.42M | 33.10M | 19.34M | 24.74M | 29.90M |
| Total Debt | 2.01M | 154.08K | 103.31K | 10.45M | 10.55M | 9.49M |
| Total Liabilities | 9.17M | 5.69M | 4.46M | 25.55M | 14.51M | 11.67M |
| Stockholders Equity | 137.88M | 81.89M | 33.40M | 2.22M | 12.86M | 20.39M |
Cash Flow | ||||||
| Free Cash Flow | -33.43M | -29.65M | -30.10M | -28.02M | -19.08M | -15.07M |
| Operating Cash Flow | -32.69M | -29.05M | -29.99M | -27.92M | -18.78M | -14.64M |
| Investing Cash Flow | -79.16M | -599.26K | -75.16K | -99.03K | 8.70M | -14.45M |
| Financing Cash Flow | 143.07M | 77.39M | 45.78M | 27.84M | 13.52M | 49.92M |
Eupraxia Pharmaceuticals Technical Analysis
Negative
9.74
Price Trends
9.90
Positive
10.63
Negative
9.46
Positive
Market Momentum
-0.02
Negative
49.73
Neutral
77.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EPRX, the sentiment is Negative. The current price of 9.74 is below the 20-day moving average (MA) of 9.99, below the 50-day MA of 9.90, and above the 200-day MA of 9.46, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 49.73 is Neutral, neither overbought nor oversold. The STOCH value of 77.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:EPRX.
Eupraxia Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
TSE:EPRX
Eupraxia Pharmaceuticals
9.93
4.55
84.57%
TSE:ENBI
Entheon Biomedical
0.10
>-0.01
-9.09%
TSE:DRUG
Bright Minds Biosciences
123.46
84.43
216.32%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:MBIO
Mindbio Therapeutics Corp.
0.60
-3.40
-85.00%
Eupraxia Pharmaceuticals Corporate Events
Business Operations and Strategy
Eupraxia Pharmaceuticals to Highlight Drug-Delivery Pipeline at April Investor Conferences
Positive
Apr 15, 2026
Eupraxia Pharmaceuticals, a clinical-stage biotech specializing in locally delivered, extended-release drugs based on its Diffusphere microsphere technology, is advancing a pipeline that includes EP-104GI for eosinophilic esophagitis and EP-104IAR...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Eupraxia Widens Q4 Loss but Extends Cash Runway With $63 Million Financing
Positive
Mar 13, 2026
Eupraxia Pharmaceuticals reported a wider fourth-quarter 2025 net loss of $16.7 million, compared with $7.5 million a year earlier, as it ramped research and development spending on its lead EP-104GI program and expanded general and administrative...
Business Operations and StrategyPrivate Placements and Financing
Eupraxia Raises US$55 Million to Accelerate EP-104GI and GI Pipeline
Positive
Feb 19, 2026
Eupraxia Pharmaceuticals has priced a public offering of approximately US$55 million in common shares and pre-funded warrants, with an additional 30-day option for underwriters to buy more shares, and expects the transaction to close on February 2...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Eupraxia Pharmaceuticals Plans Public Offering to Fund GI Drug Pipeline
Positive
Feb 18, 2026
Eupraxia Pharmaceuticals has filed a preliminary prospectus supplement to launch a proposed public offering of common shares, or pre-funded warrants, in Canada and the U.S., with Cantor and LifeSci Capital as joint bookrunners and Bloom Burton as ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.